Test drug ABBV-319 in B-cell blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial studies ABBV-319 given by vein to see what side effects it causes and how the cancer activity changes in certain B-cell blood cancers. It may help people with relapsed or treatment-resistant disease by exploring new treatment options and better understanding how the drug moves through the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of one of these: diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia.
- Your cancer must be measurable and meet the study’s imaging/blood-test rules for “measurable disease.”
- You must meet the lab test levels required by the protocol (blood counts, organ function, etc.).
- If you previously received a CD19-targeting therapy, you must be able to provide a tumor biopsy sample after your last CD19 treatment.
- You cannot have active disease in the brain or spinal cord (central nervous system lymphoma).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests the safety and best dose of a CD19 CAR T cell therapy (azer-cel) in people whose B-cell blood cancer has returned or did not respond to treatment. It may help people with relapsed/refractory B-ALL or certain aggressive or large B-cell lymphomas, including after or before prior CAR T treatment.
This trial tests a new drug called CC312 for people with B-cell blood cancers that have come back or stopped responding to treatment. CC312 is designed to target CD19 on cancer cells, and the study checks if it is safe and how the body handles it.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
This trial tests a new drug called A-319 that targets a protein (CD19) on leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia that has come back, did not respond to treatment, or still has small signs of cancer after chemotherapy.
This trial tests a new type of immune cell that targets two markers (CD19 and CD22) on lymphoma cells. It is for patients whose lymphoma has come back or not responded after at least two prior treatments.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.